share_log

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Mandadi Tilak

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Mandadi Tilak

西维斯健康 | 4：持股变动声明-高管 Mandadi Tilak
美股SEC公告 ·  12/04 06:17

Moomoo AI 已提取核心信息

On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.
On November 30, 2024, Tilak Mandadi, EVP and Chief DDAT Officer of CVS Health, is set to acquire 50,125 shares of Common Stock (RSU) at $59.85 per share. This transaction, classified as a "Grant, award or other acquisition," will increase Mandadi's direct ownership to 99,747 shares.The acquisition, valued at approximately $3 million, represents a significant addition to Mandadi's stake in the company. Following this transaction, Mandadi's total beneficial ownership of CVS Health common stock will amount to 40,414 shares.This stock grant appears to be part of CVS Health's executive compensation program, potentially aligning the interests of senior management with those of shareholders. The transaction is scheduled to be completed on the specified date, subject to any potential changes or company policies regarding executive stock acquisitions.
2024年11月30日，西维斯健康的执行副总裁兼首席数字数据和技术官Tilak Mandadi计划以每股59.85美元的价格收购50,125股普通股（RSU）。这笔交易被归类为“授予、奖励或其他收购”，将使Mandadi直接所有股数增加至99,747股。这项价值约300万美元的收购，将大幅增加Mandadi在该公司的持股。此次交易完成后，Mandadi对西维斯健康普通股的总受益所有权将达到40,414股。这项股票授予似乎是西维斯健康的高管薪酬计划的一部分，可能会调动高级管理层与股东的利益。预计该交易将在指定日期完成，视情况可能会有变化，或者受公司有关高管股票收购的政策约束。
2024年11月30日，西维斯健康的执行副总裁兼首席数字数据和技术官Tilak Mandadi计划以每股59.85美元的价格收购50,125股普通股（RSU）。这笔交易被归类为“授予、奖励或其他收购”，将使Mandadi直接所有股数增加至99,747股。这项价值约300万美元的收购，将大幅增加Mandadi在该公司的持股。此次交易完成后，Mandadi对西维斯健康普通股的总受益所有权将达到40,414股。这项股票授予似乎是西维斯健康的高管薪酬计划的一部分，可能会调动高级管理层与股东的利益。预计该交易将在指定日期完成，视情况可能会有变化，或者受公司有关高管股票收购的政策约束。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间